Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 550-555
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Table 5 Success rate and underlying disease: Secondary eradication therapy
| PPI group | Vonoprazan group | P value | ||
| ITT analysis | 91.5% (292/319) | 89.6% (43/48) | 0.59 | |
| Chronic gastritis | ||||
| PP analysis | 93.9% (292/311) | 100% (43/43) | 0.15 | |
| ITT analysis | 86.4% (38/44) | 100% (8/8) | 0.57 | |
| Peptic ulcer | ||||
| PP analysis | 95.0% (38/40) | 100% (8/8) | 1 | |
| ITT analysis | 78.6% (22/28) | 80% (8/10) | 1 | |
| After endoscopic therapy for early gastric cancer | ||||
| PP analysis | 78.6% (22/28) | 80% (8/10) | 1 |
- Citation: Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7(4): 550-555
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/550.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.550